复发性和第二原发头颈癌患者的生活质量
这项回顾性队列研究纳入2016至2019年头颈癌生存门诊的662例患者,其中原发546例、第二原发34例、复发82例。多模式治疗与较低UW-QOL躯体和社会情绪子量表评分相关,复发和第二原发患者接受放疗者评分更差且进食评估工具评分更高。作者认为多模式治疗更可能降低生活质量和加重症状,应与患者充分沟通。
要点
- 多模式治疗与原发头颈鳞癌患者较低的UW-QOL躯体和社会情绪评分相关。
- 复发和第二原发患者相比原发患者UW-QOL躯体评分更低。
- 复发或第二原发接受放疗者相比单纯手术UW-QOL评分更差且进食评估工具评分更高。
核心结论
- 多模式治疗,尤其在复发性和第二原发头颈鳞癌中,更可能降低生活质量和加重症状,这一重要考虑应有助于与患者进行知情讨论。
研究设计与样本
- 回顾性队列研究,纳入2016年至2019年头颈癌生存门诊就诊的患者,共662例:原发头颈鳞癌546例、第二原发头颈鳞癌34例、复发头颈鳞癌82例。
- 使用华盛顿大学生活质量问卷(UW-QOL)、10项进食评估工具、8项患者健康问卷、7项广泛性焦虑障碍量表和颈部功能障碍指数评估生活质量和症状,采用回归分析探索关联并比较生活质量结局。
主要发现
- 多模式治疗相比单一模式与更低的UW-QOL躯体子量表评分相关:化放疗为-12.17(95%CI,-16.57至-7.78),手术+术后辅助治疗为-12.11(-16.06至-8.16)。
- 多模式治疗相比单一模式也与更低的UW-QOL社会情绪子量表评分相关:化放疗为-6.70(-11.41至-1.99),手术+术后辅助治疗为-7.41(-11.63至-3.19)。
- 复发(-14.42,95%CI,-18.80至-10.04)和第二原发(-11.15,-17.71至-4.59)相比原发显示更低的UW-QOL躯体子量表评分。
- 复发或第二原发接受放疗相比单纯手术,UW-QOL躯体子量表评分更差(-10.43,95%CI,-19.27至-1.59)、社会情绪子量表评分更差(-10.58,-18.76至-1.54),且进食评估工具评分更高(6.08,1.39至10.77)。
- 手术+术后辅助治疗相比单纯手术,UW-QOL躯体子量表评分更差(-12.65,95%CI,-23.76至-1.54)、社会情绪子量表评分更差(-12.20,-22.38至-2.03)。
临床怎么用
- 作者认为多模式治疗更可能降低生活质量和加重症状,这一重要考虑应有助于与患者进行知情讨论。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: In the setting of similar outcomes, quality of life (QOL) measures can be utilized to compare treatment modalities in head and neck squamous cell carcinoma (HNSCC). We evaluate QOL and symptoms in patients treated for primary, second primary, and recurrent HNSCC. STUDY DESIGN: Retrospective cohort study. SETTING: Head and neck cancer survivorship clinic. METHODS: We identified patients seen between 2016 and 2019. QOL and symptoms were assessed with the University of Washington Quality of Life (UW-QOL) questionnaire, 10-item Eating Assessment Tool, 8-item Patient Health Questionnaire, 7-item Generalized Anxiety Disorder, and Neck Disability Index. Regression analysis was utilized to explore associations and compare QOL outcomes. RESULTS: Our cohort comprised 662 patients: 546 with primary HNSCC, 34 with second primary HNSCC, and 82 with recurrent HNSCC. Multimodality therapy was associated with lower UW-QOL Physical Subscale (UW-QOL-PS) vs single modality: chemoradiation therapy (-12.17 [95% CI, -16.57 to -7.78]) and surgery + postadjuvant treatment (-12.11 [-16.06 to -8.16]). Multimodality therapy was also associated with lower UW-QOL Social-Emotional Subscale (UW-QOL-SS): chemoradiation therapy (-6.70 [-11.41 to -1.99]) and surgery + postadjuvant treatment (-7.41 [-11.63 to -3.19]). Recurrence (-14.42 [-18.80 to -10.04]) and second primary (-11.15 [-17.71 to -4.59]) demonstrated lower UW-QOL-PS vs primary. Radiation for recurrence or second primary had worse UW-QOL-PS (-10.43 [-19.27 to -1.59]) and UW-QOL-SS (-10.58 [-18.76 to -1.54]) and higher Eating Assessment Tool (6.08 [1.39-10.77]) than surgery alone. Surgery + postadjuvant treatment showed worse UW-QOL-PS (-12.65 [-23.76 to -1.54]) and UW-QOL-SS (-12.20 [-22.38 to -2.03]). CONCLUSION: Multimodality therapy, particularly with recurrent and second primary HNSCC, is more likely to contribute to diminished QOL and symptoms. This important consideration should play a role in framing informed discussions with patients regarding treatment.
引用
- Ramprasad VH, Li J, Atchison K, et al. Quality of Life in Patients With Recurrent and Second Primary Head and Neck Cancer. Otolaryngol Head Neck Surg. 2023. PMID: 35316115. doi:10.1177/01945998221087712
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。